CLINICAL TRIALS PROFILE FOR TICLID

All Clinical Trials for TICLID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01823185 ↗	Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy	Unknown status	Dammam Central Hospital	Phase 4	2013-03-01	Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications. However, clopidogrel is ineffective in certain patients due to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of clopidogrel. Therefore, the purpose of this study is to test these patients genetically at bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) if they are carriers of the allele 2 or 3 of the mutated gene.
NCT01823185 ↗	Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy	Unknown status	King Fahad Armed Forces Hospital	Phase 4	2013-03-01	Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications. However, clopidogrel is ineffective in certain patients due to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of clopidogrel. Therefore, the purpose of this study is to test these patients genetically at bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) if they are carriers of the allele 2 or 3 of the mutated gene.
NCT01823185 ↗	Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy	Unknown status	Dammam University	Phase 4	2013-03-01	Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications. However, clopidogrel is ineffective in certain patients due to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of clopidogrel. Therefore, the purpose of this study is to test these patients genetically at bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) if they are carriers of the allele 2 or 3 of the mutated gene.

Clinical Trial Conditions for TICLID

Condition Name

Condition Name for TICLID
Intervention	Trials
Myocardial Infarction	1
Thrombosis	1
Vascular Disease	1
Angina Pectoris	1

Condition MeSH

Condition MeSH for TICLID
Intervention	Trials
Vascular Diseases	1
Embolism	1
Thrombosis	1
Coronary Disease	1

Clinical Trial Locations for TICLID

Trials by Country

Trials by Country for TICLID
Location	Trials
Saudi Arabia	1

Clinical Trial Progress for TICLID

Clinical Trial Phase

Clinical Trial Phase for TICLID
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for TICLID
Clinical Trial Phase	Trials
Unknown status	1

Clinical Trial Sponsors for TICLID

Sponsor Name

Sponsor Name for TICLID
Sponsor	Trials
King Fahad Armed Forces Hospital	1
Dammam University	1
Dammam Central Hospital	1

Sponsor Type

Sponsor Type for TICLID
Sponsor	Trials
Other	3